A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment

Trial Profile

A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Bioverativ
  • Most Recent Events

    • 31 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 31 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top